chr7-44145279-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2_SupportingPM5_SupportingPP2PP3
This summary comes from the ClinGen Evidence Repository: The c.1255T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to leucine at codon 419 (p.(Phe419Leu)) of NM_000162.5. GCK is defined by the ClinGen MDEP VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.957, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in three unrelated individuals with diabetes, however PS4_Moderate cannot be applied because this number is below the MDEP threshold (PMIDs: 17204055, 20337973, 16602010, internal lab contributors). One of these individuals had a clinical history consistent with GCK-hyperglycemia; however, PP4 is unable to be evaluated due to insufficient clinical information (PMIDs: 17204055, 20337973, 16602010). Another missense variant, c.1256T>C p.Phe419Ser, has been classified as likely pathogenic by the ClinGen MDEP VCEP (PM5_Supporting). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PP2, PP3, PM2_Supporting, PM5_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA367397316/MONDO:0015967/086
Frequency
Consequence
NM_000162.5 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GCK | NM_000162.5 | c.1255T>C | p.Phe419Leu | missense_variant, splice_region_variant | 10/10 | ENST00000403799.8 | NP_000153.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GCK | ENST00000403799.8 | c.1255T>C | p.Phe419Leu | missense_variant, splice_region_variant | 10/10 | 1 | NM_000162.5 | ENSP00000384247.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
GCK-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 19, 2022 | The GCK c.1255T>C variant is predicted to result in the amino acid substitution p.Phe419Leu. This variant has been reported in individuals with maturity-onset diabetes of the young (MODY) (Inoue et al. 2004. PubMed ID: 15102714; Pinterova et al. 2007. PubMed ID: 17204055; Supplemental Table S1, Osbak et al. 2009. PubMed ID: 19790256; Pruhova et al. 2010. PubMed ID: 20337973) and in individuals with asymptomatic hyperglycemia (Feigerlová et al. 2006. PubMed ID: 16602010). Of note, this variant was identified in one family with MODY, however the variant was 83.3% penetrant in that family (Inoue et al. 2004. 15102714). The p.Phe419Leu variant was detected near a putative MgATP binding site and could thus affect binding kinetics (Pinterova et al. 2007. PubMed ID: 17204055). Other variants impacting the p.Phe419 amino acid have also been reported in individuals with MODY (p.Phe419Val, Supplemental Table S1, Osbak et al. 2009. PubMed ID: 19790256; p.Phe419Ser, Valentínová et al. 2012. PubMed ID: 22493702; p.Phe419Cys, Haliloglu et al. 2016. PubMed ID: 27256595). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Taken together, we interpret the c.1255T>C (p.Phe419Leu) variant as likely pathogenic. - |
Maturity onset diabetes mellitus in young Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic | - | Potent mutations in GCK gene is associated with poor secretion of insulin. Its associated with milder forms of diabetes, which can be controlled by diet . However, there is no sufficient evidence to ascertain the significance of rs1554334478 in MODY, yet. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 12, 2017 | - - |
Monogenic diabetes Uncertain:1
Uncertain significance, reviewed by expert panel | curation | ClinGen Monogenic Diabetes Variant Curation Expert Panel | Aug 26, 2023 | The c.1255T>C variant in the glucokinase gene, GCK, causes an amino acid change of phenylalanine to leucine at codon 419 (p.(Phe419Leu)) of NM_000162.5. GCK is defined by the ClinGen MDEP VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.957, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in three unrelated individuals with diabetes, however PS4_Moderate cannot be applied because this number is below the MDEP threshold (PMIDs: 17204055, 20337973, 16602010, internal lab contributors). One of these individuals had a clinical history consistent with GCK-hyperglycemia; however, PP4 is unable to be evaluated due to insufficient clinical information (PMIDs: 17204055, 20337973, 16602010). Another missense variant, c.1256T>C p.Phe419Ser, has been classified as likely pathogenic by the ClinGen MDEP VCEP (PM5_Supporting). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PP2, PP3, PM2_Supporting, PM5_Supporting. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at